Genetic Polymorphisms of Cytochrome P450 Enzymes Influence Metabolism of the Antidepressant Escitalopram and Treatment Response

• Robinson OJ , SahakianBJ: Recurrence in major depressive disorder: a neurocognitive perspective.Psychol. Med.38 , 315–318 (2008).
   PubMed Web of Science ®Google Scholar
• Baldwin DS , ReinesEH, GuitonC, WeillerE: Escitalopram therapy for major depression and anxiety disorders.Ann. Pharmacother.41 , 1583–1592 (2007).
   PubMed Web of Science ®Google Scholar
• Rao N : The clinical pharmacokinetics of escitalopram.Clin. Pharmacokinet.46 , 281–290 (2007).
   PubMed Web of Science ®Google Scholar
• Kobayashi K , ChibaK, YagiT et al.: Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.J. Pharmacol. Exp. Ther.280 , 927–933 (1997).
   PubMed Web of Science ®Google Scholar
• von Moltke LL , GreenblattDJ, GiancarloGM et al.: Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.Drug Metab. Dispos.29 , 1102–1109 (2001).
   PubMed Web of Science ®Google Scholar
• Reis M , LundmarkJ, BengtssonF: Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992–1997.Ther. Drug Monit.25 , 183–191 (2003).
   PubMed Web of Science ®Google Scholar
• Yu BN , ChenGL, HeN et al.: Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.Drug Metab. Dispos.31 , 1255–1259 (2003).
   PubMed Web of Science ®Google Scholar
• Maron E , TammisteA, KallassaluK et al.: Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.Eur. Neuropsychopharmacol.19 , 451–456 (2009).
   PubMed Web of Science ®Google Scholar
• Tian C , GregersenPK, SeldinMF: Accounting for ancestry: population substructure and genome-wide association studies.Hum. Mol. Genet.17 , R143–R150 (2008).
   PubMed Web of Science ®Google Scholar
• Sheng HH , ZengAP, ZhuWX et al.: Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population.Acta Pharmacol. Sin.28 , 279–286 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Barcelo M , ChowLY, ChiuHF et al.: Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population.Clin. Chem.46 , 18–23 (2000).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M : Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.Pharmacogenomics J.5 , 6–13 (2005).
   PubMed Web of Science ®Google Scholar
• Ismail R , TehLK, AmirJ, AlwiZ, LopezCG: Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia.J. Clin. Pharm. Ther.28 , 279–284 (2003).
   PubMed Web of Science ®Google Scholar
• Ji L , PanS, Marti-JaunJ et al.: Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese.Clin. Chem.48 , 983–988 (2002).
   PubMed Web of Science ®Google Scholar
• Johansson I , OscarsonM, YueQY et al.: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.Mol. Pharmacol.46 , 452–459 (1994).
   PubMed Web of Science ®Google Scholar
• Solus JF , AriettaBJ, HarrisJR et al.: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.Pharmacogenomics5 , 895–931 (2004).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , BradfordLD, AlanderSW, LeederJS: CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status.Drug Metab. Dispos.34 , 563–569 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou H -H: Genetic polymorphism of CYP2C19 in Chinese ethnic populations. International Congress Series1244 , 51–61 (2002).
   Google Scholar
• Horai Y , NakanoM, IshizakiT et al.: Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.Clin. Pharmacol. Ther.46 , 198–207 (1989).
   PubMed Web of Science ®Google Scholar
• Sim SC , RisingerC, DahlML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Clin. Pharmacol. Ther.79 , 103–113 (2006).
   PubMed Web of Science ®Google Scholar
• Rudberg I , MohebiB, HermannM, RefsumH, MoldenE: Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.Clin. Pharmacol. Ther.83 , 322–327 (2008).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M , SimSC, GomezA, Rodriguez-AntonaC: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.Pharmacol. Ther.116 , 496–526 (2007).
   PubMed Web of Science ®Google Scholar
• Dai D , TangJ, RoseR et al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.J. Pharmacol. Exp. Ther.299 , 825–831 (2001).
   PubMed Web of Science ®Google Scholar
• Qiu XY , JiaoZ, ZhangM et al.: Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.Eur. J. Clin. Pharmacol.64 , 1069–1084 (2008).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, The Fourth Edition, Text-Revised. American Psychiatric Publisher, Washington, DC, USA (2000).
   Google Scholar
• Hamilton M : Development of a rating scale for primary depressive illness.Br. J. Soc. Clin. Psychol.6 , 278–296 (1967).
   PubMed Web of Science ®Google Scholar
• Uhr M , TontschA, NamendorfC et al.: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.Neuron57 , 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• Hamilton M : A rating scale for depression.J. Neurol. Neurosurg. Psychiatr.23 , 56–62 (1960).
   PubMed Web of Science ®Google Scholar
• Seretti A , CusinC, LattuadaE et al.: Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders.Mol. Psychiatry4 , 280–283 (1999).
   PubMed Web of Science ®Google Scholar
• McGahuey CA , GelenbergAJ, LaukesCA et al.: The Arizona Sexual Experience Scale (ASEX): reliability and validity.J. Sex Marital Ther.26 , 25–40 (2000).
   PubMed Web of Science ®Google Scholar
• Kristoffersen L , BuggeA, LundanesE, SlordalL: Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection.J. Chromatogr. B. Biomed. Sci. Appl.734 , 229–246 (1999).
   PubMed Web of Science ®Google Scholar
• Kubota T , YamauraY, OhkawaN, HaraH, ChibaK: Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.Br. J. Clin. Pharmacol.50 , 31–34 (2000).
   PubMed Web of Science ®Google Scholar
• Bodin L , BeaunePH, LoriotMA: Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR.J. Biomed. Biotechnol.2005 , 248–253 (2005).
   PubMedGoogle Scholar
• Steen VM , AndreassenOA, DalyAK et al.: Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.Pharmacogenetics5 , 215–223 (1995).
   PubMedGoogle Scholar
• Wigginton JE , CutlerDJ, AbecasisGR: A note on exact tests of Hardy–Weinberg equilibrium.Am. J. Hum. Genet.76 , 887–893 (2005).
   PubMed Web of Science ®Google Scholar
• Schenk PW , van Fessem MA, Verploegh-van Rij S et al.: Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol. Psychiatry13 , 597–605 (2008).
   PubMed Web of Science ®Google Scholar
• Liang KY , ZegerSL: Longitudinal data analysis using generalized linear models.Biometrika73 , 13–22 (1986).
   Web of Science ®Google Scholar
• Eichelbaum M , Ingelman-SundbergM, EvansWE: Pharmacogenomics and individualized drug therapy.Annu. Rev. Med.57 , 119–137 (2006).
   PubMed Web of Science ®Google Scholar
• Bertilsson L , LouYQ, DuYL et al.: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.Clin. Pharmacol. Ther.51 , 388–397 (1992).
   PubMed Web of Science ®Google Scholar
• Steimer W , ZopfK, von Amelunxen S et al.: Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem.50 , 1623–1633 (2004).
   PubMed Web of Science ®Google Scholar
• Hinrichs JW , LooversHM, ScholtenB, van der Weide J: Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur. J. Clin. Pharmacol.64 , 979–986 (2008).
   PubMed Web of Science ®Google Scholar

▪ Websites

• The Human Cytochrome P450 (CYP) Allele Nomenclature commitee (Updated 21 April 2008) www.cypalleles.ki.se/cyp2d6.htm
   Google Scholar
• Clinical trials.gov: clinical pharmacogenomics of antidepressant response www.clinicaltrial.gov/ct/show/NCT00384020
   Google Scholar